Optimistic
Last updated: 2026-07-06 17:32:08 ET
ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.
AbbVie (NYSE:ABBV – Get Free Report) had its target price boosted by analysts at Cantor Fitzgerald from $240.00 to $265.00 in a research report...
AMAT, MA, ABBV, VATE and BOF headline new research reports highlighting AI, payments, healthcare and microcap growth opportunities.
Eli Lilly and Company, AbbVie, and Pfizer are the three Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that develop, manufacture, and sell medi...
Research Analysts’ downgrades for Sunday, July 5th: AbbVie (NYSE:ABBV) was downgraded by analysts at Wall Street Zen from a strong-buy rating to a buy rating. ACRES Commercial Realty (NYSE:ACR) was downgraded by analysts at Wall Street Zen fro...
In late June 2026, AbbVie reported multiple product wins, including new pediatric approvals for SKYRIZI, positive CHMP opinions for RINVOQ in alopecia areata and non-segmental vitiligo, and strong Phase 3 lymphoma data for epcoritamab plus lenalidomi...
Hudson Edge Investment Partners Inc. increased its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 7.2% during the first quarter, Holdings Channel reports. The firm owned 32,743 shares of the company’s stock after buying an additio...
Price-action only: Abbvie Inc. (ABBV) movements set the tone for institutional models. (ABBV) and the Role of Price-Sensitive Allocations
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE